Novaremed AG is a clinical-stage Swiss biopharmaceutical company focused on the development of NRD.E1, an orally active New Chemical Entity (NCE) for the treatment of Neuropathic Pain.
Its fully-owned subsidiary, Novaremed Ltd. was founded in Israel in 2008, where a successful Phase IIa Proof of Concept (PoC) study in Diabetic Neuropathic Pain (DNP) was completed.
In 2017, Novaremed AG was incorporated in Basel, Switzerl...
Novaremed AG is a clinical-stage Swiss biopharmaceutical company focused on the development of NRD.E1, an orally active New Chemical Entity (NCE) for the treatment of Neuropathic Pain.
Its fully-owned subsidiary, Novaremed Ltd. was founded in Israel in 2008, where a successful Phase IIa Proof of Concept (PoC) study in Diabetic Neuropathic Pain (DNP) was completed.
In 2017, Novaremed AG was incorporated in Basel, Switzerland, which is one of the most important biotech and pharma clusters in Europe to gain access to experienced clinical development staff and investor capital.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.